Stockreport

Travere Therapeutics Reports Third Quarter 2025 Financial Results

Travere Therapeutics, Inc.  (TVTX) 
PDF U.S. net product sales of FILSPARI® (sparsentan) grew 155% year-over-year to $90.9 million in 3Q 2025; 731 new PSFs received during the quarterTotal revenue for 3Q 2025 [Read more]